UCB SA Cash Flow Conversion Efficiency
UCB SA cash flow conversion efficiency. Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.032x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€369.00 Million ≈ $431.40 Million USD) by net assets (€11.65 Billion ≈ $13.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see UCB SA market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of UCB SA (2000–2025)
Cash flow conversion efficiency of UCB SA from 2000 to 2025. This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View UCB SA (UCB) share price today for real-time trading data and today's change.
UCB SA Cash Flow Conversion Ratio Explained
UCB SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
UCB SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency. Review how much free cash does UCB SA generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
3I GROUP PLC ADR 1/2
F:IGQ
|
N/A |
|
RIO Tinto Ltd
AU:RIO
|
0.151x |
|
Chunghwa Telecom Co
TW:2412
|
0.081x |
|
ERSTE GP BNK AG ADR 1/2
F:EBOR
|
0.070x |
|
FORTESCUE MET.GR.SP.ADR 2
F:FVJA
|
N/A |
|
Roper Technologies Inc
NASDAQ:ROP
|
0.025x |
|
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
|
0.037x |
|
Semiconductor Manufacturing Intl Co
SHG:688981
|
0.028x |
Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)
The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025. Also see UCB total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.87 Billion ≈ $12.70 Billion |
€2.16 Billion ≈ $2.53 Billion |
0.199x | +60.72% |
| 2024-12-31 | €10.03 Billion ≈ $11.72 Billion |
€1.24 Billion ≈ $1.45 Billion |
0.124x | +46.05% |
| 2023-12-31 | €8.97 Billion ≈ $10.49 Billion |
€761.00 Million ≈ $889.69 Million |
0.085x | -31.32% |
| 2022-12-31 | €9.06 Billion ≈ $10.60 Billion |
€1.12 Billion ≈ $1.31 Billion |
0.123x | -33.34% |
| 2021-12-31 | €8.39 Billion ≈ $9.80 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.185x | +24.58% |
| 2020-12-31 | €7.27 Billion ≈ $8.50 Billion |
€1.08 Billion ≈ $1.26 Billion |
0.149x | +18.13% |
| 2019-12-31 | €7.01 Billion ≈ $8.19 Billion |
€882.00 Million ≈ $1.03 Billion |
0.126x | -27.72% |
| 2018-12-31 | €6.25 Billion ≈ $7.31 Billion |
€1.09 Billion ≈ $1.27 Billion |
0.174x | +7.73% |
| 2017-12-31 | €5.74 Billion ≈ $6.71 Billion |
€927.00 Million ≈ $1.08 Billion |
0.162x | +107.29% |
| 2016-12-31 | €5.48 Billion ≈ $6.40 Billion |
€427.00 Million ≈ $499.21 Million |
0.078x | +75.76% |
| 2015-12-31 | €5.55 Billion ≈ $6.48 Billion |
€246.00 Million ≈ $287.60 Million |
0.044x | -60.71% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€552.00 Million ≈ $645.35 Million |
0.113x | +69.44% |
| 2013-12-31 | €4.32 Billion ≈ $5.05 Billion |
€288.00 Million ≈ $336.70 Million |
0.067x | -13.81% |
| 2012-12-31 | €4.59 Billion ≈ $5.37 Billion |
€355.00 Million ≈ $415.03 Million |
0.077x | +27.66% |
| 2011-12-31 | €4.82 Billion ≈ $5.64 Billion |
€292.00 Million ≈ $341.38 Million |
0.061x | -45.06% |
| 2010-12-31 | €4.59 Billion ≈ $5.37 Billion |
€506.00 Million ≈ $591.57 Million |
0.110x | +64.99% |
| 2009-12-31 | €4.42 Billion ≈ $5.16 Billion |
€295.00 Million ≈ $344.89 Million |
0.067x | -26.70% |
| 2008-12-31 | €4.02 Billion ≈ $4.70 Billion |
€366.00 Million ≈ $427.89 Million |
0.091x | -20.71% |
| 2007-12-31 | €4.26 Billion ≈ $4.99 Billion |
€490.00 Million ≈ $572.86 Million |
0.115x | +71.05% |
| 2006-12-31 | €4.78 Billion ≈ $5.59 Billion |
€321.00 Million ≈ $375.28 Million |
0.067x | -44.19% |
| 2005-12-31 | €2.41 Billion ≈ $2.82 Billion |
€290.00 Million ≈ $339.04 Million |
0.120x | -67.06% |
| 2004-12-31 | €1.96 Billion ≈ $2.30 Billion |
€718.17 Million ≈ $839.61 Million |
0.365x | -3.84% |
| 2003-12-31 | €1.78 Billion ≈ $2.09 Billion |
€677.97 Million ≈ $792.61 Million |
0.380x | -0.34% |
| 2002-12-31 | €1.57 Billion ≈ $1.83 Billion |
€596.97 Million ≈ $697.92 Million |
0.381x | +11.99% |
| 2001-12-31 | €1.39 Billion ≈ $1.63 Billion |
€473.45 Million ≈ $553.51 Million |
0.341x | +18.59% |
| 2000-12-31 | €1.21 Billion ≈ $1.41 Billion |
€346.26 Million ≈ $404.81 Million |
0.287x | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more